A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies

A post marketing surveillance to determine the type and incidence of oro/nasopharyngeal or pulmonary adverse events that may occur in patients treated with commercially available Tyvaso®(treprostinil) Inhalation Solution. A comparison will be made to the type and incidence of events in patients receiving other FDA approved therapies for pulmonary arterial hypertension, as a control measure.

Inclusion Criteria:

• Clinical diagnosis of PAH, WHO GROUP I
• Prescribed and is currently receiving Tyvaso and/or other FDA-approved therapy for the treatment of PAH
• Willing and able to provide written informed consent

Exclusion Criteria:

• Previous initiation and permanent discontinuation of Tyvaso
• Participation in an investigational clinical drug or device trial within 30 days of enrollment
• Current or past diagnosis of lung neoplasm
• Active gastrointestinal or pulmonary bleed at enrollment
• Planned surgical intervention for treatment of PAH e.g., atrial septostomy or transplant

community centers, academic institutions